Norges Bank
AIMT

Norges Bank’s Aimmune Therapeutics AIMT Stock Holding History

Norges Bank’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-145,222
Closed -$5M – 2209
2020
Q3 		$5M Sell
145,222
-325,802
-69% -$6.94M ﹤0.01% 1865
2020
Q2 		$7.87M Sell
471,024
-22,915
-5% -$389K ﹤0.01% 1780
2020
Q1 		$7.12M Hold
493,939
– – ﹤0.01% 1731
2019
Q4 		$16.5M Buy
493,939
+71,254
+17% +$1.99M ﹤0.01% 1621
2019
Q3 		$8.85M Buy
422,685
+127,852
+43% +$2.61M ﹤0.01% 1818
2019
Q2 		$6.14M Hold
294,833
– – ﹤0.01% 1910
2019
Q1 		$6.59M Buy
294,833
+42,517
+17% +$1M ﹤0.01% 1900
2018
Q4 		$6.04M Hold
252,316
– – ﹤0.01% 1887
2018
Q3 		$6.88M Hold
252,316
– – ﹤0.01% 1915
2018
Q2 		$6.79M Buy
252,316
+31,695
+14% +$970K ﹤0.01% 1899
2018
Q1 		$7.02M Buy
+220,621
New +$7.76M ﹤0.01% 1836
2017
Q1 		– Sell
-61,500
Closed -$1.26M – 2204
2016
Q4 		$1.26M Buy
+61,500
New +$1.26M ﹤0.01% 2010

Norges Bank's AIMT Position: Q4 2020 in Review

Norges Bank sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 145,222 shares — an estimated $5M sold.

Norges Bank first reported a position in AIMT in Q4 2016 and held it in 12 quarters. The position peaked at $16.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Norges Bank reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Norges Bank sold 145,222 Aimmune Therapeutics shares in Q4 2020, an estimated $5M.
  • Norges Bank first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 12 quarters.
  • Norges Bank's Aimmune Therapeutics position peaked at $16.5M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Norges Bank's 13F filing for Q4 2020, filed 10 Feb 2021.